Compare FLNG & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | ANIP |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2019 | 1999 |
| Metric | FLNG | ANIP |
|---|---|---|
| Price | $30.66 | $78.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $23.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 376.6K | 274.5K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | N/A | $21.01 |
| Revenue Next Year | $2.14 | $17.59 |
| P/E Ratio | ★ $19.72 | $61.35 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $23.66 | $62.61 |
| 52 Week High | $33.40 | $99.50 |
| Indicator | FLNG | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 41.72 |
| Support Level | $30.60 | $76.92 |
| Resistance Level | $31.31 | $83.66 |
| Average True Range (ATR) | 0.83 | 2.38 |
| MACD | 0.10 | -0.59 |
| Stochastic Oscillator | 62.63 | 18.11 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.